Medtronic stock expands neurovascular portfolio with new guidewire

Published on 11/11/2026 at 17:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic stock draws focus after the Aristotle Mini Guidewire launch. The device expands access options for complex neurovascular procedures.

Medtronic expands neurovascular access

The Aristotle Mini Guidewire follows FDA 510(k) clearance in August and targets smaller, more distal neurovascular anatomy.
The device complements Medtronic's Onyx liquid embolic system in chronic subdural hematoma procedures.
Broader availability is planned after an initial phased commercial launch and physician experience.

Medtronic plc, IE00BTN1Y115, Illustration mit AI erstellt.

Medtronic has expanded its neurovascular portfolio with the launch of the Aristotle Mini Guidewire, following U.S. Food and Drug Administration 510(k) clearance in August. The company announced the launch on Monday, November 9, in a Medtronic business and regional news release.

Lower-profile access targets complex anatomy

The new guidewire is designed to help physicians navigate smaller, more distal vessels in procedures including middle meningeal artery embolization for chronic subdural hematoma. Medtronic said the device complements its Onyx liquid embolic system and other neurovascular technologies.

Aristotle Mini is compatible with 0.013-inch inner-diameter microcatheter workflows. The company also said the guidewire may support procedures involving arteriovenous malformations and dural arteriovenous fistulas, where access to small vessels can be critical.

Commercial rollout remains phased

Medtronic plans an initial commercial rollout, with broader availability after early physician experience. That timing gives investors a near-term product milestone but does not yet provide a sales forecast, procedure target or revenue contribution.

Medtronic stock traded at 91.02 euros on Lang & Schwarz at 17:36 CET on Wednesday, November 11, 2026.